

# RECEIVED

OCT 0 7 2002

TC 1700

**PATENT** 

Docket No. 2710-4011US1

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Michael B. CHANCELLOR, et al.

Serial No

10/081,835

Group Art Unit: 1722

Filed

February 22, 2002

Examiner: TBA

For

RAPID PREPARATION OF STEM CELL MATRICES FOR USE IN TISSUE AND

ORGAN TREATMENT AND REPAIR

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:

This Supplemental Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1.	[ ] For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:				
2.	[ ] For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.				
3.	[ ] Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No, filed				

4.	[X] No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:					
•	[]	37 C.F.R. §1.97(b)(1), within three months of the filing date of the above-identified application for filing date of the continued prosecution application filed on; or				
	[]	37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or				
	[X]	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office Action on the merits, whichever event occurred last.				
5.	[ ] No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.					
6.	[ ] A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):					
	[]	A check in the amount of \$240.00 is enclosed in payment of the fee.				
	[]	Charge the fee to Deposit Account No. 13-4500. Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.				
7.	compliance	due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever but before payment of the issue fee, and is accompanied by:				
	a. [ ]	one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and				
	b. [ ]	the attached petition requesting consideration of this Information Disclosure Statement; and				
	c. [ ]	the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.				
3.	[ ] A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with:					
	a. [ ]	37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;				
	b. [ ]	37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanies by the attached Petition To withdraw Application From Issue.				
	c. [ ]	The fee due under 37 C.F.R. §1.17(i)(1) is paid as set forth in paragraph 10 below.				

Serial No. 10/081,835 Docket No. <u>2710-4011US1</u>

9.	[X] I hereby certify that each item of information contained in the Information Disclosure Statement was cited in
	a communication from a foreign patent office in a counterpart foreign application not more than three months
	prior to the filing of this Information Disclosure Statement.

- [ ] I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after make reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- 10. [ ] A check in the amount of \$130.00 is enclosed in payment of the fee due under C.F.R. §1.17(i)(1).
  - [ ] Charge the fee due under C.F.R. §1.17(i)(1) to Deposit Account No. 13-4500. Order No. \_\_\_\_\_\_. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
  - [X] The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2710-4011US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: October 2, 2002

Lesle A. Serunian Registration No. 35,353

**CORRESPONDENCE ADDRESS:** 

MORGAN & FINNEGAN, L.L.P 345 Park Avenue New York, New York 10154 (212) 758-4800 (212) 751-6849 Facsimile

FORM: IDS.NY Rev. 05/26/98

INFORMATIO	ORM PTO-1449 ON DISCLOSURE CI	TATION A	ttorney Docket: '10-4011US1	Serial No.: 10/081,835		
		A <sub>1</sub> M	oplicant: ichael B. Chancellor, et al.			
			ling Date: bruary 22, 2002	Group Art Unit: 1722		
		U.S. P	ATENT DOCUMENTS			
Examiner Initial	Patent Number	Issue Date	Name	Class	Sub-Class	Filing Date
	5,863,531	Jan. 26, 1999	Naughton, et al.	424	93.7	Jun. 7, 1995
	6,174,333	Jan. 16, 2001	Kadiyala, et al.	623	11.11	Dec. 29, 1998
	6,306,424	Oct. 23, 2001	Vyakarnam, et al.	424	426	Dec. 21, 1999
	6,299,905	Oct. 9, 2001	Peterson, et al.	424	486	Apr. 16, 1996
	6,348,069	Feb. 19, 2002	Vacanti, et al.	623	11.11	Nov. 3, 1998
				RECEIV	ED	
				OCT 0 7 200		
				TC 170	0	
		FOREIG	N PATENT DOCUMENTS	<u> </u>		
Examiner Initial	Patent Number	Publication Date	Country	Class	Sub-Class	Translati n
						Yes No
						Yes No
						Yes No
						Yes No
						Yes No
	OTHE	R DOCUMEN	TS (Including Author, Titl	e, Date, etc.)		

Examiner		Date Considered
EXAMINER:	Initial if reference considered, whether or not citation is in conform Draw line through citation if not in conformance and not considered Include copy of this form with next communication to Applicant.	



Docket No. 2710-4011US1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

0-05-06

Applicant(s):

M.B. CHANCELLOR et al.

Group Art Unit:

1722

Serial No.:

10/081,835

Examiner:

To Be Assigned

Filed:

February 22, 2002

For:

RAPID PREPARATION OF STEM CELL MATRICES FOR USE IN TISSUE AND

ORGAN TREATMENT AND REPAIR

### **EXPRESS MAIL CERTIFICATE**

Express Mail Label No.:

EL 912003701 US

Date of Deposit:

October 2, 2002

I hereby certify that the following attached paper(s) and/or fee

1. Supplemental Information Disclosure Statement (3 pages);

2. PTO-1449 Form listing 5 references (1 page);

3. Copies of 5 references listed on Form PTO-1449 (92 total pages);

4. Return Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, Washington, DC 20231

Jafet N. Cotto

(Typed or printed name of person mailing papers(s) and/or fee)

Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.

345 Park Avenue

New York, NY 10154-0053

(212) 758-4800 Telephone

(212) 751-6849 Facsimile

RECEIVED

OCT 0 7 2002

TC 1700